_pennystock版 - (ZT) 5 Cheap Biotech Stocks That May Rebound Ahead of the Market |
|---|
|
|
|
|
|
p********e
发帖数: 1960 | 1 DNDN, KERX, BPAX, CHTP, OPXA
http://seekingalpha.com/article/286963-5-cheap-biotech-stocks-t
Most biotech stocks have experienced very sharp drops as the markets have
plummeted over economic concerns. However, biotechs are not as economically
sensitive as other companies and therefore are likely to rebound sharply in
the coming days. These dirt cheap biotech companies all have interesting
products in the pipeline which could become major catalysts in the future.
The lower priced stocks tend to have more risk, but far more potential
reward. The stocks below are trading at valuations that appear to be a
buying opportunity that could provide for very substantial gains. Positive
results on clinical trials, partnership agreements, and other news are just
some of the catalysts that could send these stocks much higher. Almost all
of these biotech companies have substantial amounts of cash or cash
equivalents on their balance sheets. Most of them have either little to no
long term debt.
Below, I detail why these biotech stocks could be poised for major gains in
the near future. Here are the stocks that have upside potential of about 200
% to even about 600% in the long term and 50-100% in the short term:
Dendreon Corporation (DNDN) is trading around $9.91. Dendreon is a
biotechnology company, based in Washington. These shares have traded in a
range between $9.80 to $43.96 in the last 52 weeks. The 50 day moving
average is $36.32 and the 200 day moving average is $36.57.
Why Dendreon shares could surge higher: This stock dropped off a cliff
several days ago when Dendreon announced financial results. Investors were
not pleased with slower than expected sales for Provenge as well as concerns
of reimbursement. The stock is deeply oversold and should see at least a
short term bounce in the coming days which could be a good trading
opportunity.
Biosante Pharmaceuticals, Inc. (BPAX) is trading around $2.17. Biosante is a
biotechnology company, based in Illinois. These shares have traded in a 52
week range between $1.29 to $2.60. The 50 day moving average is $2.98 and
the 200 day moving average is $2.18. Earnings estimates for BPAX are for a
loss of 49 cents per share for 2011 and loss of 13 cents for 2012.
Why Biosante shares could surge higher: BPAX has a licensing agreement with
Teva Pharmaceuticals (TEVA) for Bio-T-Gel which treats low testosterone
levels. The NDA is pending with the FDA for this product and Teva is
responsible for all regulatory and marketing. BPAX also has the right to
receive up to $140 million in sales-based milestone payments from Azur for "
Elestrin" (which targets estrogen) if it reaches certain predefined sales
per calendar year.
Opexa Therapeutics, Inc. (OPXA) is trading at $1.23. Opexa is a
biotechnology company, based in Texas. These shares have traded in a 52 week
range between $1.02 to $2.99. The 50 day moving average is $1.54 and the
200 day moving average is $1.71. This company has a great balance sheet,
with about $11 million in cash and almost no debt. They also have a
potential Multiple Sclerosis (MS) treatment called "Tovaxin" with
blockbuster potential and phase 3 clinical trials for Tovaxin are scheduled
to start in the second half of 2011. This stock is cheaper now than it was
under a recent offering made a couple of months ago.
Opexa sold shares at $2.05 in a public offering of 4,146,500 shares, which
resulted in gross proceeds of $8,500,325. According to Opexa's website:
Opexa's lead therapy, Tovaxin®, a cellular immunotherapy has completed a
Phase 2b clinical study for the treatment of MS which is specifically
tailored to each patient's disease profile. Opexa believes the potential
combination of efficacy, superior safety, excellent tolerability and
administration may position Tovaxin as the MS treatment of choice as
compared to existing therapeutics.
Why Opexa shares could surge higher: There are multiple reasons why Opexa
stock could surge. Like many biotech stocks there is a large short interest
of about 720,000 shares in Opexa, so any goods news or new interest in the
stock often leads to a major spike in the share price, causing a short
covering frenzy. Just days ago the stock spiked to $1.75 with no news
released by the company, in what seemed to be a mini short covering rally.
This shows just how quick the stock could go up on pipeline or partnership
news.
According to analysts at Vista Partners:
Biogen Idec is actively seeking acquisitions and partnership opportunities
in MS and we believe Opexa is an attractive acquisition and partnership as
the company's lead compound Tovaxin is scheduled to commence Phase III
trials in the second half of 2011.
Vista Partners recently came out with a price target of $6.50 for OPXA due
to the stock being very undervalued for a company that is close to starting
phase 3 trials and also due to the possibility that Opexa could be an
interesting takeover target or partner with a major pharmaceutical company
like Biogen (BIIB). With shares trading under $1.50 and a target price of $6
.50, this stock has big potential.
Chelsea Therapeutics (CHTP) is trading around $3.93. CHTP is a biotechnology
company, based in North Carolina. These shares have traded in a range
between $2.81 to $8.20 in the last 52 weeks. The 50 day moving average is $4
.99 and the 200 day moving average is $5.04.
Why Chelsea shares could surge higher: Chelsea is pursuing an orphan drug
strategy for a drug called Northera (Droxidopa) which is for the treatment
of hypotension (yes, that's Hypotension, not hypertension). This treatment
has been approved and marketed in Japan for over 15 years, and generates
about $50 million in revenue in that country.
Recently, Chelsea released positive data on this drug and it caused an
analyst to raise the price target to $18 due to their belief this will be
approved early in 2012. If the price target of $18 is reached, investors
buying now will gain over 500%. CHTP has a high short interest so these
shares could also head higher in a short squeeze.
Keryx Biopharmaceuticals, Inc. (KERX) is trading around $2.99. Keryx is a
biotechnology company, based in New York. These shares have traded in a 52
week range between $3. to $5.91. The 50 day moving average is $4.58 and the
200 day moving average is $4.66. Earnings estimates for KERX are for a loss
of 35 cents per share for 2011 and loss of 41 cents for 2012. Keryx has a
number of interesting candidates in the product development pipeline. This
company has two candidates "Perifosine" for multiple myeloma and colorectal
cancer and "Zerenex" which targets hyperphosphatemia in patients with end-
stage renal disease, both of which are currently in phase 3 trials.
Why KERX shares could surge higher: MLV Capital recently put a buy rating on
KERX with an $18 price target. See that here: finviz.com/quote.ashx If the
price target of $18 is reached, investors buying now will gain over 500%.
The data is sourced from Yahoo Finance, and Stockcharts.com. The information
and data is believed to be accurate, but no guarantees or representations
are made. Rougemont is not a registered investment advisor and does not
provide specific investment advice. The information contained herein is for
educational purposes only. | M***m
发帖数: 762 | 2 good today...
economically
in
【在 p********e 的大作中提到】
: DNDN, KERX, BPAX, CHTP, OPXA
: http://seekingalpha.com/article/286963-5-cheap-biotech-stocks-t
: Most biotech stocks have experienced very sharp drops as the markets have
: plummeted over economic concerns. However, biotechs are not as economically
: sensitive as other companies and therefore are likely to rebound sharply in
: the coming days. These dirt cheap biotech companies all have interesting
: products in the pipeline which could become major catalysts in the future.
: The lower priced stocks tend to have more risk, but far more potential
: reward. The stocks below are trading at valuations that appear to be a
: buying opportunity that could provide for very substantial gains. Positive
| p********e
发帖数: 1960 | 3 DNDN endorsed by 银杏
KERX endorsed by Laoniu
BPAX endorsed by Laoniu |
|
|
|
|
|
|
